Bonfiglio V, et al. - Researchers assessed the impacts of intravitreal dexamethasone implant (DEX) in patients with diabetic macular edema (DME) unresponsive to ranibizumab treatment, relative to the inflammatory optical coherence tomography (OCT) retinal features, subfoveal neuroretinal detachment (SND) and hyperreflective retinal spots (HRS). In identifying some inflammatory features in DME, utility of spectral domain OCT was noted. Compared to the eyes without SND and HRS, those with these features responded better to DEX implants in DME eyes “poorly responsive” to ranibizumab.